GU Cancer

Ovarian cancer screening picks up earlier stage disease but prognosis remains unchanged

The largest ovarian cancer screening trial to date has found no benefit on prognosis from annual serum CA125 measurements or transvaginal ultrasound screening in women aged between 50 and 74. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) showed no significant reduction in deaths from ovarian or tubal cancer after 16 years of follow ...

Already a member?

Login to keep reading.

© 2022 the limbic